Equities research analysts expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating) to announce sales of $1.45 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Aeglea BioTherapeutics’ earnings, with the lowest sales estimate coming in at $1.40 million and the highest estimate coming in at $1.50 million. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Aeglea BioTherapeutics will report full year sales of $5.50 million for the current year, with estimates ranging from $5.00 million to $6.00 million. For the next year, analysts forecast that the firm will post sales of $17.14 million, with estimates ranging from $10.23 million to $29.21 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Aeglea BioTherapeutics.
Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) last posted its quarterly earnings results on Tuesday, March 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.01. The business had revenue of $3.64 million for the quarter, compared to analysts’ expectations of $3.07 million.
In related news, CEO Anthony G. Quinn acquired 67,472 shares of the business’s stock in a transaction that occurred on Monday, March 14th. The stock was purchased at an average cost of $1.93 per share, for a total transaction of $130,220.96. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Anthony G. Quinn acquired 34,777 shares of the business’s stock in a transaction dated Friday, March 11th. The stock was purchased at an average cost of $2.06 per share, with a total value of $71,640.62. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 257,328 shares of company stock worth $545,246. 3.80% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the company. Laurion Capital Management LP increased its stake in shares of Aeglea BioTherapeutics by 139.1% in the fourth quarter. Laurion Capital Management LP now owns 1,450,638 shares of the biotechnology company’s stock worth $6,891,000 after buying an additional 844,000 shares during the last quarter. Suvretta Capital Management LLC boosted its stake in Aeglea BioTherapeutics by 19.2% during the fourth quarter. Suvretta Capital Management LLC now owns 2,571,000 shares of the biotechnology company’s stock valued at $12,212,000 after buying an additional 413,273 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Aeglea BioTherapeutics by 698.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 227,508 shares of the biotechnology company’s stock worth $1,081,000 after purchasing an additional 199,005 shares in the last quarter. ClariVest Asset Management LLC acquired a new position in shares of Aeglea BioTherapeutics in the 4th quarter worth $832,000. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Aeglea BioTherapeutics by 55.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 416,174 shares of the biotechnology company’s stock worth $1,977,000 after buying an additional 149,108 shares during the period. 83.22% of the stock is owned by institutional investors.
AGLE stock opened at $1.56 on Friday. Aeglea BioTherapeutics has a 52-week low of $1.47 and a 52-week high of $8.50. The firm has a market cap of $77.00 million, a P/E ratio of -1.56 and a beta of 1.43. The company’s 50-day simple moving average is $2.32 and its 200-day simple moving average is $4.30.
Aeglea BioTherapeutics Company Profile (Get Rating)
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.
- Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
- Iridium Communications Stock is Ready to Return to Orbit
- O’Reilly Automotive Hits A Pothole
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
- Harley-Davidson Skids Into A Buying Opportunity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.